Bristol Myers Squibb partners with Microsoft to use AI for early lung cancer detection in U.S. healthcare systems. AI tools will analyze X-ray and CT images to detect lung nodules early, reducing clinical workload and improving patient care. The initiative aims to help underserved populations with higher lung cancer death rates. Microsoft’s AI platform will assist clinicians in identifying potential cancer cases earlier. Microsoft’s pre-market trading is down 1.36% at $453.61 on Nasdaq, while Bristol Myers Squibb is down 0.45% at $55.02 on NYSE.

Read more at Nasdaq: Bristol Myers Squibb Partners With Microsoft On AI Lung Cancer Detection